Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single Continuous Intravenous Injection, Dose Escalation, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of M201-A in Healthy Japanese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Dec 2021
Price :
$35
*
At a glance
- Drugs M201-A (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions; First in man
- 28 Nov 2021 Status changed from recruiting to completed.
- 23 Feb 2017 New trial record